Profound Medical to to Participate in the 2023 Bloom Burton & Co. Healthcare Investor Conference
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) will present an update on its business at the Bloom Burton & Co. Healthcare Investor Conference on April 26, 2023, at 10:00 a.m. Eastern Time, held at the Metro Toronto Convention Centre. The presentation will be accessible via live broadcast and archived on the Company's website under the Investors section.
Profound specializes in incision-free therapies for ablation of diseased tissue, including their advanced TULSA-PRO® technology, which combines MRI imaging with focused ultrasound for customizable prostate treatments. TULSA-PRO® is FDA cleared and CE marked. The Company also offers Sonalleve®, a platform for treating uterine fibroids and palliative treatments for bone metastases, which holds various international approvals. For more details, visit www.profoundmedical.com.
- None.
- None.
TORONTO, April 19, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company’s business at the Bloom Burton & Co. Healthcare Investor Conference on Wednesday, April 26, 2023 at 10:00 a.m. Eastern Time at the Metro Toronto Convention Centre.
The presentation will be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investors section.
About Profound Medical Corp.
Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities. TULSA-PRO® has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large volume benign prostatic hyperplasia (“BPH”). TULSA-PRO® is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).
Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve® has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve® where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.
For further information, please contact:
Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849
FAQ
What event is Profound Medical Corp. attending on April 26, 2023?
Where will the Bloom Burton & Co. Healthcare Investor Conference be held?
What time is Profound Medical's presentation scheduled for?
How can I access the presentation by Profound Medical Corp.?
What technologies does Profound Medical specialize in?
